New virus-based immune therapy for hard-to-treat B-cell lymphoma

Plain-English translation of NCT07398963 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new experimental therapy called RGV005, which uses a modified virus to deliver immune-fighting instructions directly to lymphoma cancer cells. The treatment is designed for people whose B-cell lymphoma has come back or stopped responding to standard chemotherapy and other treatments. Researchers will test the medication in two ways: injecting it directly into tumors or infusing it through the bloodstream, and they'll gradually increase doses to find the safest and most effective level.

Standard treatments for B-cell lymphoma don't work for all patients, and some people's cancer comes back after initial therapy. This study exists to explore whether this new virus-based approach can help patients whose cancer has become resistant to conventional options.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with B-cell lymphoma that has either come back after treatment or stopped responding to at least two rounds of prior therapy
your cancer cells are CD19-positive (confirmed by a lab test)
you have at least one tumor that is large enough to be measured by imaging scans
your heart, liver, and kidney function are reasonably good based on recent blood tests
you are willing to use effective birth control for at least 60 days after treatment ends

You likely don't qualify if…

you have received a smallpox vaccine in the past 3 months
you have received other gene therapy or oncolytic virus therapy in the past 3 months
you have an active infection that is not controlled, or you have HIV, hepatitis B, hepatitis C, or untreated syphilis
you have a history of severe allergic reactions to smallpox vaccine, or you are allergic to albumin or egg products
you are pregnant, breastfeeding, or unwilling to use birth control

What participation looks like

You will receive either an injection directly into one of your tumors or an infusion through your vein, depending on which group you're assigned to. You'll start at a low dose, and if it's well-tolerated, new participants will receive gradually higher doses. After your treatment, you'll have a follow-up visit at 3 months, and then you'll continue in a long-term follow-up program for 3 years where the research team will monitor how you're doing and check for side effects.

AI-generated summary from trial data · Aug 17, 2026 · Not medical advice

Trial locations(1 site)

China

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang